Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Stice

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Circulation Research|October 31, 2009
Extracellular heat shock protein 60, cardiac myocytes, and apoptosisSe-Chan Kim, James P Stice, Le Chen, et al.
Circulation Research|January 20, 2007
Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alphaHarold J Ting, James P Stice, Ulrich Y Schaff, et al.
Molecular Cancer Research : MCR|February 18, 2017
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPCJames P Stice, Suzanne E Wardell, John D Norris, et al.
Nature Chemical Biology|August 9, 2016
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancerJulie A Pollock, Suzanne E Wardell, Alexander A Parent, et al.
The Journal of Clinical Investigation|May 3, 2017
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerJohn D Norris, Stephanie J Ellison, Jennifer G Baker, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibitionKatherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Cancer Discovery|December 6, 2024
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12CAnna E Maciag, James P Stice, Bin Wang, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Circulation Research|October 31, 2009
Extracellular heat shock protein 60, cardiac myocytes, and apoptosisSe-Chan Kim, James P Stice, Le Chen, et al.
Circulation Research|January 20, 2007
Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alphaHarold J Ting, James P Stice, Ulrich Y Schaff, et al.
Molecular Cancer Research : MCR|February 18, 2017
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPCJames P Stice, Suzanne E Wardell, John D Norris, et al.
Nature Chemical Biology|August 9, 2016
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancerJulie A Pollock, Suzanne E Wardell, Alexander A Parent, et al.
The Journal of Clinical Investigation|May 3, 2017
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerJohn D Norris, Stephanie J Ellison, Jennifer G Baker, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibitionKatherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Cancer Discovery|December 6, 2024
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12CAnna E Maciag, James P Stice, Bin Wang, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Pageof 2